Title

Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial

Authors

ADER^{1,2}, Nathan PEIFFER-SMADJA^{3,4,5}, Julien POISSY⁶, Florence BOUSCAMBERT-DUCHAMP^{7,8}, Drifa BELHADI^{3,9}, Alpha DIALLO¹⁰, Christelle DELMAS¹¹, Juliette SAILLARD¹¹, Aline DECHANET¹², Noémie MERCIER¹⁰, Axelle DUPONT^{9,12}, Toni ALFAIATE^{9,12}, François-Xavier LESCURE^{3,4}, François RAFFI^{14,15}, François GOEHRINGER¹⁶, Antoine KIMMOUN¹⁷, Stéphane JAUREGUIBERRY^{18,19}, Jean REIGNIER²⁰, Saad NSEIR⁶, François DANION²¹, Raphael CLERE-JEHL^{22,23}, Kévin BOUILLER^{24,25}, Jean-Christophe NAVELLOU²⁶, Violaine TOLSMA²⁷, André CABIE^{28,29} Clément DUBOST^{30,31}, Johan COURJON^{32,33}, Sylvie LEROY^{34,35,36}, Joy MOOTIEN³⁷, Rostane GACI³⁸, Bruno MOURVILLIER^{39,40}, Emmanuel FAURE^{41,42}, Valérie POURCHER^{43,44}, Sébastien GALLIEN^{45,46}, Odile LAUNAY⁴⁷, Karine LACOMBE^{43,48}, Jean-Philippe LANOIX^{49,50}, Alain MAKINSON^{51,52}, Guillaume MARTIN-BLONDEL^{53,54}, Lila BOUADMA^{3,55}, Elisabeth BOTELHO-NEVERS^{56,57,58}, Amandine GAGNEUX-BRUNON^{56, 57,58}, Olivier EPAULARD^{,59,60,61}, Lionel PIROTH^{62,63,64}, Florent WALLET⁶⁵, Jean-Christophe RICHARD^{66,67}, Jean REUTER⁶⁸, Thérèse STAUB⁶⁹, Maya HITES⁷⁰, Marion NORET⁷¹, Claire ANDREJAK⁷², Gilles PEYTAVIN^{3,73}, Bruno LINA^{7,8} Dominique COSTAGLIOLA**⁴³, Yazdan YAZDANPANAH**^{3,4}, Charles BURDET***^{3,9,12}, France MENTRE***^{3,9,12}, on behalf of the DisCoVeRy study group[#].

^{**} co-before-last authors

^{***} co-last authors

[#]Full list in the Supplementary Appendix

Author affiliations

- ¹ Hospices Civils de Lyon, Département des maladies infectieuses et tropicales, F-69004, Lyon, France.
- ² Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, Lyon, France.
- ³ Université de Paris, IAME, INSERM, F-75006 Paris, France.
- ⁴ AP-HP, Hôpital Bichat, Service de maladies infectieuses et tropicales, F-75018 Paris, France.
- ⁵ National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
- ⁶ Université de Lille, Inserm U1285, CHU Lille, Pôle de réanimation, CNRS, UMR 8576 UGSF Unité de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France.
- ⁷ Laboratoire de Virologie, Institut des Agents Infectieux de Lyon, Centre National de Référence des virus respiratoires France Sud, Hospices Civils de Lyon, F-69317, Lyon, France.
- ⁸ Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372, Lyon, France.
- ⁹ AP-HP, Hôpital Bichat, Département d'Épidémiologie, Biostatistique et Recherche Clinique, F-75018 Paris, France.
- ¹⁰ ANRS, France Recherche Nord & Sud Sida-hiv Hépatites, Agence autonome de l'INSERM, F-75013 Paris, France
- ¹¹ Institut de santé publique, Pôle recherche clinique, INSERM, F-75013 Paris, France.
- ¹² AP-HP, Hôpital Bichat, Unité de Recherche Clinique, F-75018 Paris, France.
- ¹³ CIC-EC 1425, INSERM, F-75018 Paris, France.

- ¹⁴ CHU de Nantes, Hôpital Hôtel-Dieu, Département des maladies infectieuses, Nantes, France.
- ¹⁵ CIC-EC 1413, INSERM, Nantes, France.
- ¹⁶ Université de Lorraine, CHRU-Nancy, Service de maladies infectieuses et tropicales, F-54000 Nancy, France.
- ¹⁷ Université de Lorraine, CHRU de Nancy, Service de médecine intensive et rénaimation Brabois, Inserm U1116, F-CRIN INI CRCT, 54000 Nancy, France.
- ¹⁸ AP-HP, Service des maladies infectieuses, Hôpital Bicêtre, F- 94270 Le Kremlin Bicêtre, France.
- ¹⁹ AP-HP, Centre National de Référence du Paludisme, Paris, France.
- ²⁰ CHU Nantes, Médecine intensive Réanimation, Université de Nantes, Nantes, France.
- ²¹ Hôpitaux Universitaires de Strasbourg, Service des maladies infectieuses et tropicales, F-67091 Strasbourg, France.
- ²² Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, F-67091 Strasbourg, Cedex, France.
- Université de Strasbourg, ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg, F-67091 Strasbourg, France.
- ²⁴ Centre Hospitalier Universitaire Besançon, Service des maladies infectieuses et tropicales, F-25030 Besançon, France.
- ²⁵ UMR-CNRS 6249 Chrono-environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
- ²⁶ Centre Hospitalier Universitaire Besançon, Service de réanimation médicale, F-25030 Besançon, France.

- ²⁷ Centre Hospitalier Annecy Genevois, Service des maladies infectieuses et tropicales, F-74374 Annecy, France.
- ²⁸ Université des Antilles, INSERM CIC 1424, EA4537, Martinique, France.
- ²⁹ CHU de Martinique, Service des maladies infectieuses et tropicales, Martinique, France.
- ³⁰ Hôpital Militaire Bégin, Service de réanimation polyvalente, F-94160 Saint-Mandé, France.
- ³¹ Université Paris-Saclay, ENS Paris-Saclay, CNRS, Centre Borelli, F-91190 Gif-sur-Yvette, France.
- ³² CHU de Nice, Service des maladies infectieuses et tropicales, Nice, France.
- ³³ Université Côte d'Azur, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Virulence Microbienne et Signalisation Inflammatoire, INSERM, Nice, France.
- ³⁴ Fédération Hospitalo-Universitaire OncoAge, Nice, France
- ³⁵ CHU de Nice, Département de pneumologie et d'oncologie, F-06000 Nice, France.
- ³⁶ Université Côte d'Azur, CNRS UMR 7275 IPMC, Sophia Antipolis, France.
- ³⁷ Groupe Hospitalier de la région Mulhouse Sud-Alsace, Service de réanimation médicale, Mulhouse, France.
- ³⁸ CHR Metz-Thionville, Service de réanimation polyvalente, Ars-Laquenexy, France.
- ³⁹ CHU de Reims, Service de réanimation médicale, Reims, France.
- ⁴⁰ Université de Reims Champagne-Ardenne, France.
- ⁴¹ Université de Lille Nord de France, Faculté de Médecine de Lille, Lille, France.
- ⁴² CHRU Lille, Service des maladies infectieuses et tropicales, F-59000, Lille, France.
- ⁴³ Sorbonne Université, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, INSERM, F-75013, Paris, France.
- ⁴⁴ AP-HP, Hôpital Pitié-Salpêtrière, Département des maladies infectieuses et tropicales, F-75013 Paris, France.

- ⁴⁵AP-HP, Hôpital Henri Mondor, Service d'immunologie et maladies infectieuses, F-94000 Créteil, France
- ⁴⁶ Université Paris-Est Créteil, INSERM U955, F-94000 Créteil, France.
- ⁴⁷ CIC 1417, INSERM, F-75006 Paris, France.
- ⁴⁸ APHP, Hôpital Saint-Antoine, Service de maladies infectieuses et tropicales, F-75012 Paris, France.
- ⁴⁹ CHU Amiens-Picardie, Service de maladies infectieuses et tropicales, F-80000 Amiens, France.
- ⁵⁰ Université Picardie Jules Verne, AGIR UR UPJV 4294, CURS, F-80000 Amiens, France.
- ⁵¹ CHU de Montpellier, Département des maladies infectieuses, UMI 233 Inserm U1175, F-34000 Montpellier, France,
- ⁵² Inserm Clinical Investigation Center 1411, Montpellier, France.
- ⁵³ Centre Hospitalier Universitaire de Toulouse, Service des maladies infectieuses et Tropicales, F-31320 Toulouse, France.
- ⁵⁴ Université de Toulouse Paul Sabatier, Centre de Physiopathologie de Toulouse-Purpan INSERM UMR1043, F-31320 Toulouse, France.
- ⁵⁵ AP-HP, Hôpital Bichat-Claude Bernard, Service de réanimation médicale et infectieuse, F-75018 Paris, France.
- ⁵⁶CHU de Saint-Etienne, Service d'Infectiologie, F- 42055 Saint-Etienne, France.
- ⁵⁷ Université Jean Monnet, Groupe Immunité des Muqueuses et Agents Pathogènes EA 3064, F- 42023 Saint-Etienne, France.
- ⁵⁸ CIC 1408, INSERM, F- 42055 Saint-Etienne, France.
- ⁵⁹ CHU Grenoble Alpes, Service des maladies Infectieuses, F-38000 Grenoble, France.
- ⁶⁰ Université Grenoble Alpes, Fédération d'infectiologie multidisciplinaire de l'arc alpin, F-38000 Grenoble, France.

- ⁶¹ Institut de Biologie Structurale, "Virus humains persistants" Team, UMR 5075 CEA-CNRS-UGA, F-38000 Grenoble, France.
- ⁶² CHU de Dijon, Département de maladies infectieuses, F-21000, Dijon, France.
- ⁶³ Université Bourgogne Franche-Comté, LNC UMR 1231, INSERM, F-21000, Dijon, France.
- ⁶⁴ FCS Bourgogne-Franche Comté, LipSTIC LabEx, F-21000, Dijon, France.
- ⁶⁵ Hospices Civils de Lyon, Hôpital Lyon-Sud Pierre-Bénite, Département de soins intensifs, F-69000, Lyon, France.
- ⁶⁶ Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Service de réanimation médicale, F-69000, Lyon, France.
- ⁶⁷ Université Lyon I, CREATIS, CNRS UMR5220, INSERM U1044, INSA, F-69000, Lyon, France.
- ⁶⁸ Centre hospitalier de Luxembourg, Service de réanimation-soins intensifs, L-1210 Luxembourg, Luxembourg.
- ⁶⁹ Centre hospitalier de Luxembourg, Service des maladies infectieuses, L-1210 Luxembourg, Luxembourg.
- Cliniques Universitaires de Bruxelles-Hôpital Érasme, Université Libre de Bruxelles, Clinique des maladies infectieuses, Brussels, Belgium.
- ⁷¹ RENARCI, Réseau national de recherche clinique en infectiologie, France.
- ⁷² CHU d'Amiens, Département de pneumologie, F-80000 Amiens, France.
- ⁷³AP-HP, Hôpital Bichat Claude Bernard, Laboratoire de toxicologie, F-75018 Paris, France.

Corresponding author

Florence Ader, M.D., Ph.D. Département des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004 Lyon,

France. Phone number: +33 (0)472 071 560; Fax: +33 (0)472 072 441; Email:

florence.ader@chu-lyon.fr

words: COVID-19; SARS-CoV-2; hydroxychloroguine; interferon beta-1a;

lopinavir/ritonavir; randomized controlled trial

Abstract

Background: Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)- β -1a and

hydroxychloroquine efficacy for COVID-19 have been evaluated, but detailed evaluation is

lacking.

Objective: To determine the efficacy of lopinavir/ritonavir, lopinavir/ritonavir-IFN-β-1a,

hydroxychloroquine or remdesivir for improving the clinical, virological outcomes in

COVID-19 inpatients.

Design: Open-label, randomized, adaptive, controlled trial.

Setting: Multi-center trial with patients from France.

Participants: 583 COVID-19 inpatients requiring oxygen and/or ventilatory support

Intervention: Standard of care (SoC, control), SoC plus lopinavir/ritonavir (400 mg lopinavir

and 100 mg ritonavir every 12h for 14 days), SoC plus lopinavir/ritonavir plus IFN-\u00b1-1a (44

μg of subcutaneous IFN-β-1a on days 1, 3, and 6), SoC plus hydroxychloroquine (400 mg

twice on day 1 then 400 mg once daily for 9 days) or SoC plus remdesivir (200 mg

intravenously on day 1 then 100 mg once-daily for hospitalization duration or 10 days).

Measurements: The primary outcome was the clinical status at day 15, measured by the

WHO 7-point ordinal scale. Secondary outcomes included SARS-CoV-2 quantification in

respiratory specimens and safety analyses.

Results: Adjusted Odds Ratio (aOR) for the WHO 7-point ordinal scale were not in favor of

investigational treatments: lopinavir/ritonavir versus control, aOR 0.83, 95%CI, 0.55 to 1.26,

P=0.39; lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69, 95%CI, 0.45 to 1.04, P=0.08;

hydroxychloroquine versus control, aOR 0.93, 95%CI, 0.62 to 1.41, P=0.75. No significant

effect on SARS-CoV-2 RNA clearance in respiratory tract was evidenced.

Lopinavir/ritonavir-containing treatments were significantly associated with more SAE.

Limitations: Not a placebo-controlled, no anti-inflammatory agents tested.

Conclusion: No improvement of the clinical status at day 15 nor SARS-CoV-2 RNA clearance in respiratory tract specimens by studied drugs. This comforts the recent Solidarity findings.

Registration: NCT04315948.

Funding: PHRC 2020, Dim OneHealth, REACTing

Introduction

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) emerged in China in December 2019, subsequently causing a worldwide pandemic(1, 2).

While waiting for specific therapeutic treatments and/or vaccines against SARS-CoV-2, efforts initially focused on repurposing drugs that have previously shown broad-spectrum antiviral activity against other coronaviruses. Lopinavir/ritonavir, type I interferon (IFN), hydroxychloroquine, and remdesivir were among the first investigational treatments to be tested on the basis of their *in vitro* activity against SARS-CoV-2(3-9). Activity of combined anti-HIV agent lopinavir/ritonavir against novel coronaviruses occurs *via* inhibition of 3-chymotrypsin-like protease-dependent proteolysis preventing cleavage into viral proteins(3, 4). Activity of hydroxychloroquine occurs *via* affecting early stage of viral replication through increased endosomal pH resulting in inhibition of virus-endosome fusion(7-9). Activity of type I IFN is mediated by the heightening of antiviral cellular immune defenses(10). In addition, it was hypothesized that hydroxychloroquine and type I IFN may have intrinsic immunomodulatory effects(10-12). Remdesivir is an adenosine analogue, which incorporates into nascent viral RNA chains and results in pre-mature termination(13).

The DisCoVeRy trial is a phase 3 multicenter, open-label, randomized, adaptive, controlled trial to evaluate the clinical and the virological efficacy, as well as the safety, of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a, hydroxychloroquine, and remdesivir as compared with standard of care in adults hospitalized for COVID-19 (14). The DisCoVeRy trial is part of the international Solidarity trial consortium sponsored by the World Health Organization (WHO). Interim results of the Solidarity trial were recently published. They were restricted to the analysis of in-hospital mortality, need for mechanical ventilation and time to hospital discharge. No treatment exhibited a significant effect on these critical

outcomes when compared to standard of care(15). The DisCoVeRy trial provides more

detailed data on safety and clinical and laboratory surrogates, in particular virological data.

We report here the results from the lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and

hydroxychloroquine arms, which were prematurely stopped. The remdesivir arm is continuing

and currently enrolling.

Methods

Trial design and oversight

DisCoVeRy is an open-label, adaptive, multicenter, randomized controlled trial which

evaluates the efficacy and safety of drugs in adults hospitalized for COVID-19.

Sponsored by the Institut national de la santé et de la recherche médicale (Inserm, France), the

trial was approved by the Ethics Committee (CPP Ile-de-France-III, approval

#20.03.06.51744). Written informed consent was obtained from all included participants or

their legal representative if they were not able to consent. The trial was conducted in

accordance with the Declaration of Helsinki and national laws and regulations and declared

on the clinicatrials.gov registry (NCT 04315948) and on the European Clinical Trials

Database (2020-000936-23). The present analysis is based on the protocol v7.0 of April, 5th

2020,(14) with two secondary outcomes added in protocol v9.0 of June, 29th 2020.

Participants

Eligible participants were adults (≥ 18-year old) hospitalized with a PCR-proven (< 72 hours)

SARS-CoV-2 infection and pulmonary rales or crackles with a peripheral oxygen saturation ≤

94%, or requirement of supplemental oxygen. Exclusion criteria included a contraindication

to any of the investigational treatment or their use within 29 days before randomization;

elevated liver enzyme > 5 times the upper limit, an estimated glomerular filtration rate below

30 mL/min, pregnancy or breast-feeding. Full inclusion and exclusion criteria are presented in

the Supplementary Appendix.

Interventions and randomization

Participants were randomly assigned in a 1:1:1:1:1 ratio through computer-generated blocks of various sizes and stratified by administrative region and severity of illness at enrolment (moderate disease: hospitalized participants receiving low-flow supplemental oxygen or not requiring oxygen; severe disease: hospitalized participants requiring non-invasive ventilation or high-flow oxygen devices, invasive mechanical ventilation or ECMO). Randomization was implemented in the electronic Case Report Form to ensure appropriate allocation concealment. Investigational arms were standard of care (SoC, control), SoC plus lopinavir/ritonavir (tablets or oral suspension in nasogastric tube of 400 mg lopinavir and 100 mg ritonavir administered every 12h for 14 days), SoC plus lopinavir/ritonavir plus IFN-\(\textit{B}\)-1a (44 \(\mu\)g of subcutaneous IFN-\(\textit{B}\)-1a on days 1, 3, and 6), SoC plus hydroxychloroquine (200 mg tablets adjusted to 400 mg twice on day 1 as a loading dose followed by 400 mg once daily for 9 days)(16) or SoC plus remdesivir (200 mg intravenously on day 1 as a loading dose followed by 100 mg once-daily for hospitalization duration or 10 days). Other supportive treatments, such as glucocorticoids or immunomodulatory agents, were allowed in all arms.

Clinical and laboratory monitoring

Participants were assessed daily while hospitalized, and at days 3, 5, 8, 11, 15±2 and 29±3 if they were withdrawn at these dates. Clinical data, concomitant medications, adverse events (AEs) and measurements for blood cell counts, serum creatinine and liver aminotransferases were collected. Nasopharyngeal swab (NPS) and lower respiratory tract (LRT, *i.e.* bronchoalveolar lavage, protected specimen brushing or bronchial aspiration) specimens were collected for SARS-CoV-2 real-time (RT) PCR.

Outcomes measures

The primary outcome measure was the clinical status at day 15 as measured on the 7-point ordinal scale of the WHO Master Protocol (v3.0, March 3, 2020): 1. Not hospitalized, no

limitation on activities; 2. Not hospitalized, limitation on activities; 3. Hospitalized, not

requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5.

Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on

invasive mechanical ventilation or ECMO; 7. Death.

Secondary efficacy outcome measures included the clinical status at day 29 and the time to an

improvement of 2 categories as measured on the 7-point ordinal scale or hospital discharge

until day 29, the time to National Early Warning Score 2 (NEWS2) ≤2 or hospital discharge

until day 29, the time to hospital discharge until day 29, oxygenation- and ventilator-free days

until day 29, 29-day mortality. Normalized SARS-CoV-2 viral loads were qualitatively and

quantitatively assessed in respiratory tract specimens (see Supplementary Appendix).

Secondary safety outcomes included the cumulative incidence of any grade 3 or 4 AE (coded

using the medical dictionary for regulatory affairs, v23.0), or of any serious adverse event

(SAE, according to the Division of AIDS (DAIDS, Table for Grading the Severity of Adult

and Paediatric Adverse Events, v2.1, July 2017) and the proportion of patients with a

premature suspension or discontinuation for any reason of the investigational treatments.

Sample size calculation

Hypotheses for sample size calculation are presented in Supplementary Appendix.

Interim analyses

An independent data safety and monitoring board (DSMB) externally reviewed the trial data.

For efficacy and futility, the statistical analysis was performed on the primary outcome

measure, and was based on the Haybittle-Peto rule(17, 18). Consistently with its role of add-

on partner trial, DisCoVeRy periodically transferred data regarding three of its secondary

outcomes to the WHO Solidarity trial: in-hospital mortality, time to hospital discharge, time

to mechanical ventilation.

On May 25th 2020, following a safety warning on hydroxychloroquine use(19), enrollment in the hydroxychloroquine arm was suspended at the request of the French Agency of drug Security (Agence Nationale de Sécurité du Médicament). On June 13th, based on the interim analysis of the Solidarity data, the Solidarity and DisCoVeRy trial DSMBs recommended to definitely stop the hydroxychloroquine arm due to futility. This decision was endorsed by the DisCoVeRy steering committee on June 17th. The Solidarity DSMB advised to stop the lopinavir/ritonavir arm due to futility on June, 23th. Thereafter, the DisCoVeRy DSMB further advised to stop both the lopinavir/ritonavir-containing arms due to additional safety concern on June, 25th. This decision was endorsed by the DisCoVeRy steering committee on June 27th with subsequent interruption on June, 29th.

Statistical analyses

Statistical analyses compared each of the three stopped investigational treatment arms to the control arm. Due to the slowdown of inclusions in the trial between May and July, a single patient was included in the control arm between the hydroxychloroquine arm suspension and the permanent discontinuation of the lopinavir/ritonavir-containing arms. For simplification purpose, only one control group was constituted, which included participants from the control arm included before June 29th. The intention-to-treat population included all randomized participants for whom a valid consent form was obtained. The modified intention-to-treat population included participants from the intention-to-treat population who received at least one dose of the treatment allocated by randomization.

Efficacy analyses were performed on the intention-to-treat population; handling of missing data is described in Supplementary Appendix. Safety analyses were performed on modified intention-to-treat population. Analyses were stratified by baseline severity but not by region of inclusion due to a low number of inclusions in some regions; all tests were two-sided with a type-I error of 0.05.

For the 7-point ordinal scale, data were analyzed using a proportional odds model. Time-to-event data were analyzed using a Cox proportional hazard model. An analysis of covariance was performed for the comparison of oxygenation- and ventilator-free days between groups; 29-day mortality and the number of participants with detectable SARS-CoV-2 in the respiratory tract specimens at each time point were analyzed using a Cochran-Mantel-Haenszel test. Log₁₀ normalized SARS-CoV-2 load kinetics was analyzed using a mixed-effects linear model with test of treatment effect on slopes. For safety endpoints, non-prespecified statistical comparisons of the proportions of patients with any i) adverse event, ii) grade 3 or 4 adverse event, or iii) serious adverse event between each investigational treatment arm versus control were performed using the Fisher exact test.

Role of the funding source

The trial was funded by grants from Programme Hospitalier de Recherche Clinique (PHRC-20-0351) (Ministry of Health), from the DIM One Health Île-de-France (R20117HD) and from REACTing, a French multi-disciplinary collaborative network working on emerging infectious diseases. The funding sources had no role in the analysis of the data nor in the decision of publication.

Results

Patient's characteristics at baseline

Between March, 22nd and June, 29th, 603 participants were randomized to one of the 4 arms across 32 sites in France and Luxembourg and 583 were evaluable for analysis (Supplementary Figure S1): control arm, n=148; lopinavir/ritonavir arm, n=145; lopinavir/ritonavir plus IFN-\(\beta\)-1a arm, n=145; hydroxychloroquine arm, n=145. Participants' baseline characteristics are presented in the Table 1. The median age was 63 years (IQR, 54; 71) and participants were mostly male (n=418, 71.7%). The median time from symptom onset to randomization was 9 days (IQR, 7; 12). The most frequent underlying conditions were

obesity (n=166, 28.7%), chronic cardiac disease (n=151, 26.0%) and diabetes mellitus

(n=128, 22.0%). At baseline, 211 (36.2%) participants presented a severe disease.

Concomitant treatments are presented in Supplementary Table 1. No notable imbalance

between groups was observed regarding concomitant anti-inflammatory drug used.

Primary endpoint

The distribution of the 7-point ordinal scale at day 15 is presented in the Figure 1 and Table 2.

There was no significant difference between any of the treatment arm and the control arm,

and adjusted OR (aOR) were not in favor of investigational treatments (i.e., below 1):

lopinavir/ritonavir versus control, aOR 0.83 (95% confidence interval [CI] 0.55; 1.26,

P=0.39); lopinavir/ritonavir plus IFN-\(\beta\)-1a vs. control, aOR 0.69 (95\(\circ\)CI 0.45; 1.04, P=0.08);

hydroxychloroquine vs. control, aOR 0.93 (95%CI 0.62; 1.41, P=0.75).

Secondary endpoints

The distribution of the 7-point ordinal scale at day 29 is presented in the Figure 1 and Table 2.

There was no significant difference between any of the treatment arm and the control arm.

The time to improvement of 2 categories of the 7-point ordinal scale or hospital discharge

within day 29 was significantly higher in both lopinavir/ritonavir-containing arms than in the

control arm. The time to NEWS ≤2 or hospital discharge within 29 days and time to hospital

discharge within day 29 were significantly higher in the lopinavir/ritonavir plus IFN-\u03c4-1a arm

than in the control arm (Table 2). No other significant difference was observed for any other

secondary outcomes between treatment arms and the control arm (Table 2 and Supplementary

Figures S2-S4).

Virological endpoints

No significant difference in the proportion of participants with detectable log₁₀ normalized

viral loads in NPS at each sampling time was demonstrated (Supplementary Table S2). The

proportion of participants having severe disease with detectable log₁₀ normalized viral loads in the LRT at each sampling time is presented in Supplementary Table S3.

The slope of decrease of the log_{10} normalized viral loads quantified in NPS over time was not significantly affected by any of the investigational treatment (Figure 2, panel A).

Safety

A total of 579 participants were included in the safety analysis (control, n=148; lopinavir/ritonavir, n=144; lopinavir/ritonavir plus IFN-β-1a, n=144; hydroxychloroquine, n=143). Safety outcomes are presented in the Table 3. Among the 2399 reported AEs, 477 were graded 3 or 4 in 205 patients and mostly reported in the lopinavir/ritonavir arms (Table 3).

Consistently, 608 serious adverse events (SAEs) were reported in 274 participants; 149 (24.5%) were considered to be related to the investigational drug according to investigator's judgment (accounting for 37 events in the lopinavir/ritonavir arm, 71 events in the lopinavir/ritonavir plus IFN-β-1a arm, and 41 events in the hydroxychloroquine arm). A significantly higher number of patients experienced at least one SAE in the lopinavir/ritonavir-containing arms than in the control arm (76/144, 52.8% in the lopinavir/ritonavir arm *vs.* 57/148, 38.5% in the control arm, p=0.02; 78/144, 54.2% in the lopinavir/ritonavir plus IFN-β-1a arm *vs.* 57/148, 38.5% in the control arm, p=0.01).

The most frequently reported SAEs were acute respiratory failure (n=65, 11%), acute kidney injury (n=50, 8.2%), acute respiratory distress syndrome (n=47, 8%), arrhythmia (n=41, 7%), pulmonary embolism (n=27, 5%), and sepsis including those related to super-infections (n=21, 4%). Thirteen percent (n=76) of participants developed at least one kidney-related SAE; 66 of them were critically ill ventilated patients associated with acute kidney injury or acute renal failure, of whom 12 had acute renal failure at baseline. Among the 57 fatal SAEs,

23 were classified as having a pulmonary origin, and 34 as having a non-pulmonary origin. Only 4 non-pulmonary-related deaths were linked to investigational treatments by the investigators (lopinavir/ritonavir arm, n=1; lopinavir/ritonavir plus IFN-β-1a arm, n=3).

We report here the results of the DisCoVeRy clinical trial evaluating lopinavir/ritonavir with

Discussion

or without IFN-\(\beta\)-1a, or hydroxychloroquine in comparison with control for the treatment of inpatients with COVID-19. As reported by the Solidarity interim analysis of critical endpoints, we report that these investigational treatments failed to improve the clinical course of COVID-19, nor to enhance SARS-CoV-2 clearance and were associated with more SAEs. Several larger-scale randomized controlled trials conducted in hospitalized COVID-19 patients failed to demonstrate the efficacy of hydroxychloroquine either by addressing the question through the improvement in the 7-point ordinal scale at 15 days(20) or through the effect on 28-day mortality(21) as compared to SoC alone. Our results are in line with these conclusions. We bring additional evidence that hydroxychloroquine does not accelerate SARS-CoV-2 RNA clearance, consistently with preclinical data in a macaque model(22). Two randomized trials conducted in hospitalized COVID-19 patients found no difference between the lopinavir/ritonavir and the SoC arms in terms of 28-day mortality or of probability of progression to mechanical ventilation or death(23, 24). The hypothesis that severe COVID-19 is associated with an impaired type I IFN response characterized by no or low IFN production and activity supported testing IFN with lopinavir/ritonavir. In an openlabel randomized trial, the combination of lopinavir/ritonavir, IFN-β-1b and ribavirin was superior to lopinavir/ritonavir in alleviating symptoms and shortening the duration of SARS-CoV-2 shedding in mild-to-moderate COVID-19(25). Conversely, our data suggest longer time to NEW2 improvement or hospital discharge in the lopinavir/ritonavir plus IFN-β-1a vs. lopinavir/ritonavir arm as well as no virological effect (Supplementary Figure S3). In

addition, we observed a higher rate of SAEs in the lopinavir/ritonavir-containing arms. Participants from the investigational arms experienced more acute kidney injury, although the difference was not significant. In the first series of COVID-19, acute renal failure incidence ranged from 3 to 25% among heterogeneous patients in terms of disease severity and treatment management, although predominantly in critically ill patients (26, 27). COVID-19 has been associated with renal endotheliitis(28). Elevation of serum creatinine has been associated with high levels of D-dimers (> 500 ng/mL)(29), which resonates with elevated median D-dimer levels at baseline. As reported with HIV-infected patients, infection and inflammation are associated with down-regulation of cytochrome P450(30, 31). Gregoire et al reported that intense systemic inflammatory response to SARS-CoV-2 infection enables important increase in lopinavir unbound plasma concentrations(32). Marzolini et al found that lopinavir concentrations were significantly correlated with a CRP value above 75 mg/L(33), most of our participants being above this value at baseline. Lê et al demonstrated that in mechanically-ventilated patients with COVID-19, the oral administration of lopinavir/ritonavir elicited plasma exposure of lopinavir > 6-fold the upper usual expected range(34), consistent with the fact that all kidney-related SAE occurred in critically ill ventilated patients.

DisCoVeRy is an adaptive, randomized trial initiated in France and that has been now extended to other European countries with the support of the European commission and the task of becoming a pan-European platform trial for Emerging infectious Diseases treatment. Furthermore, DisCoVeRy is an add-on trial to Solidarity and importantly contributes to Solidarity data acquisition and early interruption of treatment arms for futility. In agreement with Solidarity, our objective was to complement knowledge acquisition with granular safety and virological data. The design and the philosophy of DisCoVeRy trial will be of even greater importance when new investigational drugs will be evaluated, for which scarce safety

data might be available, unlike repurposed drugs. The trial has some limitations: it is not a placebo-controlled, double-blinded trial due to the complexity of blinding treatments with different mode of administration (intravenous, subcutaneous or oral) and the need to initiate the trial very rapidly. DisCoVeRy did not target patients at the early phase of the disease nor include arms testing anti-inflammatory agents that can be used as part of the standard of care in any arm.

Conclusion

In patients admitted to hospital with COVID-19, lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine were not associated with clinical improvement at day 15 and day 29, nor reduction in viral shedding, and generated substantial SAEs. These findings do not support the use of these investigational treatments for patients hospitalized with COVID-19.

References

- 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
- Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-6.
- 4. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875-84.

- 5. Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, et al. SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv. 2020.
- Clementi N, Ferrarese R, Criscuolo E, Diotti RA, Castelli M, Scagnolari C, et al.
 Interferon-beta-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In
 Vitro When Administered After Virus Infection. J Infect Dis. 2020;222(5):722-5.
- 7. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
- 8. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
- 9. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-9.
- 10. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791.
- 11. Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20(10):585-6.
- 12. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-74.

- 13. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-5.
- 14. Ader F, Discovery French Trial Management T. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open. 2020;10(9):e041437.
- W. H. O. Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 Interim WHO Solidarity Trial Results. N Engl J Med. 2020. doi:10.1056/NEJMoa2023184
- 16. Le MP, Peiffer-Smadja N, Guedj J, Neant N, Mentre F, Ader F, et al. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother. 2020;75(9):2376-80.
- 17. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44(526):793-7.
- Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient.
 I. Introduction and design. Br J Cancer. 1976;34(6):585-612.
- 19. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.
- Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;383(21):2041-52.

- Recovery Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40.
- 22. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020;585(7826):584-7.
- 23. Recovery Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020.
- 24. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-99.
- 25. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-704.
- 26. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am J Nephrol. 2020;51(5):343-8.
- 27. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 28. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8.

- 29. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38.
- 30. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434-8.
- 31. Ofotokun I, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, et al. Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. J Clin Pharmacol. 2011;51(11):1539-48.
- 32. Gregoire M, Le Turnier P, Gaborit BJ, Veyrac G, Lecomte R, Boutoille D, et al. Lopinavir pharmacokinetics in COVID-19 patients. J Antimicrob Chemother. 2020;75(9):2702-4.
- 33. Marzolini C, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, et al. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. Antimicrob Agents Chemother. 2020;64(9).
- 34. Lê MP, Jaquet P, Patrier J, Wicky PH, Le Hingrat Q, Veyrier M, et al. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. J Antimicrob Chemother. 2020;75(9):2657-60.

Figure 1. Clinical status, as measured by the 7-point ordinal scale, at day 15 and day 29 of patients from the intention-to-treat population of the DisCoVeRy trial, according to treatment arm and disease severity at baseline.

Reported numbers refer to the proportion of patients with the corresponding level in each group. L/r, Lopinavir/ritonavir; L/r + IFN, Lopinavir/ritonavir + interferon β -1a; HCQ, Hydroxychloroquine.





Figure 2. Evolution of the normalized SARS-CoV-2 viral load in nasopharyngeal swabs between baseline and day 15 in the intention-to-treat population of the DisCoVeRy trial: means (95%CI) of the log viral loads (panel A), mean changes from baseline (95%CI) of the log viral loads (panel B).

L/r, Lopinavir/ritonavir (blue line); L/r + IFN, Lopinavir/ritonavir + interferon β-1a (yellow line); HCQ, Hydroxychloroquine (red line); control (black line).

LSMD, least-square mean difference; 95%CI, 95% confidence interval.






Table 1. Baseline characteristics of patients included in the intention to treat population of the present analysis of DisCoVeRy trial.

NPS, Nasopharyngeal swabs; LRT, Lower respiratory tract.

* denotes variables with missing data. Data on chronic cardiac disease, chronic pulmonary disease, mild liver disease, chronic neurological disorder, active cancer and diabetes mellitus were missing for 2 patients; data on chronic kidney disease were missing for 3 patients; data on auto-inflammatory disease were missing for 1 patient; data on obesity were missing for 5 patients; data on smoking status were missing for 30 patients; data on the time from symptoms onset to randomization were missing for 8 patients; data on BMI were missing for 83 patients; data on randomization site were missing for 1 patient; data on viral load from NPS were missing for 234 patients; data on viral load from LRT specimens were missing for 527 patients; data for lymphocyte count were missing for 90 patients; data for neutrophil count were missing for 136 patients; data on creatinine were missing for 15 patients; data on AST/SGOT were missing for 56 patients; data on ALT/SGPT were missing for 51 patients; data on CRP were missing for 137 patients; data on D-Dimers were missing for 299 patients; data on PCT were missing for 356 patients; data on ferritin were missing for 421 patients.

** moderate disease: hospitalized participants receiving low-flow supplemental oxygen or not requiring oxygen; severe disease: hospitalized participants requiring non-invasive ventilation or high-flow oxygen devices, invasive mechanical ventilation or ECMO

	Overall	Control	Lopinavir/ritonavir (L/r)	Lopinavir/Ritonavir +	Hydroxychloroquine
	(N=583)	(N=148)	(N=145)	Interferon β -1a (L/r + IFN)	(HCQ)
				(N=145)	$(N=145) \qquad \stackrel{\text{a. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}}{\stackrel{\text{c.}}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}{\stackrel{\text{c. 2.}}}}{\stackrel{\text{c.}}}}{\stackrel{\text{c.}}}}}{\stackrel{\text{c.}}}}}{\stackrel{\text{c.}}}}}}}}}}}}}}}}}}}}}}}}}}}}}$
Median age — yr [IQR]	63 [54-71]	62 [52-71]	63 [55-71]	64 [53-71]	65 [55-71]
Male sex — no. (%)	418 (71.7%)	105 (70.9%)	106 (73.1%)	103 (71.0%)	Hydroxychloroquine (HCQ) (N=145) (55 [55-71] (104 (71.7%) (104 (71.7%)
Coexisting condition* — no. (%)					se.
- Chronic cardiac disease	151 (26.0%)	39 (26.4%)	35 (24.1%)	36 (25.2%)	41 (28.3%) $\frac{\Box}{g}$ 19 (13.1%)
- Chronic pulmonary disease	88 (15.1%)	31 (20.9%)	19 (13.1%)	19 (13.3%)	
- Chronic kidney disease (stage 1 to	24 (4.1%)	7 (4.7%)	2 (1.4%)	5 (3.5%)	10 (6.9%) the preprint 4 (2.8%)
3)					orep
- Mild liver disease	13 (2.2%)	6 (4.1%)	3 (2.1%)	0 (0.0%)	4 (2.8%)

	Overall (N=583)	Control (N=148)	Lopinavir/ritonavir (L/r) (N=145)	Lopinavir/Ritonavir + Interferon ß-1a (L/r + IFN)	Hydroxychloroqui (HCQ)		
	(11–303)	(11–140)	(11–143)	(N=145)	(N=145)		
Chronic neurological disorder (including dementia)	23 (4.0%)	6 (4.1%)	5 (3.4%)	4 (2.8%)	8 (5.5%)		
Active cancer	35 (6.0%)	10 (6.8%)	8 (5.5%)	6 (4.1%)	11 (7.6%)		
Auto-inflammatory disease	26 (4.5%)	8 (5.4%)	4 (2.8%)	9 (6.3%)	5 (3.4%)		
Obesity	166 (28.7%)	46 (31.3%)	36 (24.8%)	41 (28.7%)	43 (30.1%)		
Diabetes mellitus	128 (22.0%)	35 (23.6%)	35 (24.1%)	27 (18.9%)	31 (21.4%)		
Current smoker	18 (3.3%)	5 (3.5%)	4 (2.9%)	5 (3.6%)	4 (3.0%)		
Median time from symptom onset o randomization* — days [IQR]	9.0 [7.0-12.0]	10.0 [7.0-12.0]	10.0 [7.0-13.0]	10.0 [7.0-12.0]	8.0 [7.0-11.0]		
Baseline severity of COVID-19** —	no. (%)						
Moderate	372 (63.8%)	94 (63.5%)	94 (64.8%)	91 (62.8%)	93 (64.1%)		
Severe	211 (36.2%)	54 (36.5%)	51 (35.2%)	54 (37.2%) 52 (35.9%)			
Randomization site* — no. (%)							
· ICU	254 (43.6%)	64 (43.2%)	65 (44.8%)	65 (45.1%)	60 (41.4%)		
- Conventional unit (e.g. : infectious disease unit, internal medicine, pneumology)	328 (56.4%)	84 (56.8%)	80 (55.2%)	79 (54.9%)	85 (58.6%)		
7-point ordinal scale at baseline — r	no. (%)						
· 3. Hospitalized, not requiring supplemental oxygen	27 (4.6%)	8 (5.4%)	4 (2.8%)	9 (6.2%)	6 (4.1%)		
4. Hospitalized, requiring supplemental oxygen	341 (58.5%)	84 (56.8%)	88 (60.7%)	84 (57.9%)	85 (58.6%)		
- 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices	63 (10.8%)	21 (14.2%)	15 (10.3%)	13 (9.0%)	14 (9.7%)		
- 6. Hospitalized, on invasive mechanical ventilation or ECMO	152 (26.1%)	35 (23.6%)	38 (26.2%)	39 (26.9%)	40 (27.6%)		
Median NEWS-2 at baseline*,	9.0 [7.0-12.0]	9.0 [7.0-12.0]	9.0 [7.0-11.0]	10.0 [7.0-12.0]	9.0 [6.0-11.0]		

medRxiv preprint doi: https://doi.org/10.1101/2021.01.08.20248149; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Median viral load at baseline, median IQR		Overall (N=583)	Control (N=148)	Lopinavir/ritonavir (L/r) (N=145)	Lopinavir/Ritonavir + Interferon ß-1a (L/r + IFN) (N=145)	Hydroxychloroquine (HCQ) (N=145)
- Maximal neutrophils count (G/L)	median [IQR]					
- Maximal neutrophils count (G/L)	Median viral load at baseline, media	nn [IQR]	'	, in the second		'
- Maximal neutrophils count (G/L)	on NPS (log10 copies/10 000 cells)					2.0 [0.7-3.4] (n=95)
- Maximal neutrophils count (G/L)		4.1 [2.8-4.9]	3.6 [2.4-4.5]	4.4 [3.2-4.8]	3.5 [1.0-4.8]	4.3 [3.3-5.5] (n=18)
- Maximal neutrophils count (G/L)	,	, ,	(11 1 1)	, (ii 1.)	(n 10)	(11 10)
- Maximal neutrophils count (G/L)	,	i	0.9 [0.6-1.4]	0.8 [0.6-1.2]	0.9 [0.7-1.3]	0.9 [0.6-1.1]
- Maximal SGOT (U/L)						5.6 [3.8-7.8]
- Maximal SGOT (U/L)		74.0 [62.0-91.0]	72.5 [60.0-88.0]	73.5 [62.0-88.0]	77.0 [65.0-91.0]	74.0 [62.0-93.0]
- Maximal SGOT (U/L)	(μmol/L)				-	2
- Maximal plasma D-dimers (μg/L)	- Maximal SGOT (U/L)	49.0 [35.0-72.0]	53.0 [38.0-74.0]	47.0 [34.0-64.0]	47.0 [35.0-70.0]	53.5 [34.0-81.0]
- Maximal plasma D-dimers (μg/L)	- Maximal SGPT (U/L)	37.0 [25.0-63.0]	41.0 [25.0-62.0]	34.0 [22.5-60.5]	37.0 [24.0-59.0]	41.5 [26.0-67.0]
- Maximal plasma D-dimers (μg/L)	1	-	-	124.0 [75.0-188.0]	105.0 [57.0-164.0]	118.0 [72.0-188.0]
- Maximal procalcitonin (ng/mL)	(mg/L)					
1344 0] 1041 0] =	- Maximal plasma D-dimers (μg/L)	-	_	1060.0 [626.0-1987.0]	956.0 [560.0-1673.0]	1140.0 [654.0-1820.0]
1344 0] 1041 0] =	- Maximal procalcitonin (ng/mL)	0.2 [0.1-0.9]	0.3 [0.1-1.1]	0.2 [0.1-0.6]	0.3 [0.1-0.9]	0.3 [0.1-0.9]
	- Maximal ferritin (mg/L)	_	-	608.0 [2.0-1288.0]	761.0 [3.0-1344.0]	_

medRxiv preprint doi: https://doi.org/10.1101/2021.01.08.20248149; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Table 2. Primary and secondary outcomes for patients included in the present analysis DisCoVeRy trial, according to disease severity at baseline.

Analyses were stratified on the disease severity at baseline (moderate: 7-point ordinal scale 3 or 4; severe: 7-point ordinal scale 5 or 6), and adjusted effect measures are reported in the table. NP, Nasopharyngeal; LRT, Lower respiratory tract; OR, Odds-ratio; HR, Hazard ratio; LSMD, least-square mean difference.

	Ove (N=:		Con (N=1	-	. (I	r/ritonavir _/r) =145)	Lopinavir/r interfero (L/r + (N=1	on ß-1a IFN)	(He	hloroquine CQ) 145)	L/r vs. control Effect measure (95%CI)	L/r + IFN vs. control Effect measure (95%CI)	vs. control of Effect of measure (95%CI)
	Moderate (N=372)	Severe (N=211)	Moderate (N=94)	Severe (N=54)	Moderate (N=94)	Severe (N=51)	Moderate (N=91)	Severe (N=54)	Moderate (N=93)	Severe (N=52)			able u
7-point ordinal scale at day 15, n	7-point ordinal scale at day 15, n (%)												ind or/
1. Not hospitalized, no limitations on activities	84 (22.6%)	3 (1.4%)	23 (24.5%)	1 (1.9%)	21 (22.3%)	1 (2.0%)	20 (22.0%)	0 (0.0%)	20 (21.5%)	1 (1.9%)			er a C
2. Not hospitalized, limitation on activities	146 (39.2%)	16 (7.6%)	41 (43.6%)	6 (11.1%)	36 (38.3%)	2 (3.9%)	35 (38.5%)	1 (1.9%)	34 (36.6%)	7 (13.5%)			r a CC-BY-NC-
3. Hospitalized, not requiring supplemental oxygen	54 (14.5%)	22 (10.4%)	7 (7.4%)	5 (9.3%)	16 (17.0%)	5 (9.8%)	13 (14.3%)	5 (9.3%)	18 (19.4%)	7 (13.5%)	OR=0.83	OR=0.69	OR=0.9329
4. Hospitalized, requiring supplemental oxygen	41 (11.0%)	31 (14.7%)	12 (12.8%)	10 (18.5%)	9 (9.6%)	9 (17.6%)	9 (9.9%)	6 (11.1%)	11 (11.8%)	6 (11.5%)		(0.45 to 1.04) [P=0.08]	(0.62 to 1.47)
5. Hospitalized, on non- invasive ventilation or high flow oxygen devices	6 (1.6%)	10 (4.7%)	1 (1.1%)	2 (3.7%)	2 (2.1%)	1 (2.0%)	2 (2.2%)	4 (7.4%)	1 (1.1%)	3 (5.8%)		[F=0.08]	[P=0.75]:0 md
6. Hospitalized, on invasive mechanical ventilation or ECMO	27 (7.3%)	106 (50.2%)	6 (6.4%)	24 (44.4%)	7 (7.4%)	29 (56.9%)	9 (9.9%)	28 (51.9%)	5 (5.4%)	25 (48.1%)			ational license to
7. Death	14 (3.8%)	23 (10.9%)	4 (4.3%)	6 (11.1%)	3 (3.2%)	4 (7.8%)	3 (3.3%)	10 (18.5%)	4 (4.3%)	3 (5.8%)			5 6
7-point ordinal scale at day 29, n	(%)	1				1			Ĭ.	Ĭ.			978
1. Not hospitalized, no limitations on activities	146 (39.2%)	21 (10.0%)	35 (37.2%)	7 (13.0%)	36 (38.3%)	6 (11.8%)	35 (38.5%)	1 (1.9%)	40 (43.0%)	7 (13.5%)			. 10 di
2. Not hospitalized, limitation on activities	128 (34.4%)	29 (13.7%)	35 (37.2%)	5 (9.3%)	36 (38.3%)	6 (11.8%)	29 (31.9%)	8 (14.8%)	28 (30.1%)	10 (19.2%)	OR=0.93	OR=0.76	OR=1.16
3. Hospitalized, not requiring supplemental oxygen	45 (12.1%)	45 (21.3%)	12 (12.8%)	15 (27.8%)	10 (10.6%)	9 (17.6%)	11 (12.1%)	10 (18.5%)	12 (12.9%)	11 (21.2%)	(0.62 to 1.41) [P=0.74]	(0.50 to 1.15) [P=0.19]	(0.77 to 1.75) [P=0.49]
4. Hospitalized, requiring supplemental oxygen	14 (3.8%)	19 (9.0%)	4 (4.3%)	6 (11.1%)	4 (4.3%)	4 (7.8%)	4 (4.4%)	6 (11.1%)	2 (2.2%)	3 (5.8%)			reprim.

	Ove (N=:			Control (N=148)		Lopinavir/ritonavir (L/r) (N=145)		(L/r + IFN) (N=145)		ychloroquine HCQ) N=145) L/r vs. control Effect measure (95%CI)		L/r + IFN vs. control Effect measure (95%CI)	HCQ vs. contro Effect measure (95%CI
	Moderate (N=372)	Severe (N=211)	Moderate (N=94)	Severe (N=54)	Moderate (N=94)	Severe (N=51)	Moderate (N=91)	Severe (N=54)	Moderate (N=93)	Severe (N=52)			
5. Hospitalized, on non- avasive ventilation or high flow xygen devices	5 (1.3%)	10 (4.7%)	2 (2.1%)	1 (1.9%)	1 (1.1%)	2 (3.9%)	1 (1.1%)	3 (5.6%)	1 (1.1%)	4 (7.7%)			
6. Hospitalized, on invasive nechanical ventilation or ECMO	14 (3.8%)	52 (24.6%)	1 (1.1%)	13 (24.1%)	3 (3.2%)	14 (27.5%)	6 (6.6%)	13 (24.1%)	4 (4.3%)	12 (23.1%)			
7. Death	20 (5.4%)	35 (16.6%)	5 (5.3%)	7 (13.0%)	4 (4.3%)	10 (19.6%)	5 (5.5%)	13 (24.1%)	6 (6.5%)	5 (9.6%)			
Fime to improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29 (days), median [IQR]	10 [7-16]	19 [14-29]	9 [6-14]	19 [10-29]	11 [7-17]	27 [14-29]	10 [7-19]	22 [15-29]	10 [7-17]	18 [13-29]	HR=0.71 (0.54 to 0.93) [P=0.012]	HR=0.70 (0.54 to 0.92) [P=0.009]	HR=0.7 (0.61 to 1. [P=0.08
Time to National Early Varning Score ≤2 or hospital ischarge within 29 days days), median [IQR]	9 [5-16]	29 [17-29]	8 [5-14]	26 [15-29]	9 [6-16]	29 [22-29]	9 [6-18]	29 [19-29]	9 [5-15]	29 [16-29]	HR=0.83 (0.63 to 1.09) [P=0.17]	HR=0.75 (0.56 to 0.99) [P=0.046]	HR=0.9 (0.68 to 1. [P=0.45
ime to hospital discharge ithin 29 days (days), median QR]	10 [7-20]	29 [19-29]	9 [6-16]	29 [19-29]	12 [8-21]	29 [24-29]	11 [8-26]	29 [28-29]	11 [7-20]	29 [16-29]	HR=0.77 (0.58 to 1.02) [P=0.07]	HR=0.72 (0.54 to 0.96) [P=0.026]	[P=0.20
Oxygenation-free days until ay 29 (days), median [IQR]	22 [15-25]	0 [0-13]	22 [15-25]	4 [0-14]	22 [15-25]	0 [0-12]	22 [13-25]	0 [0-6]	22 [16-25]	3 [0-15]	LSMD=-0.86 (-2.80 to 1.08) [P=0.39]	LSMD=-1.68 (-3.66 to 0.29) [P=0.10]	LSMD=0 (-1.84 to 2 [P=0.87
Ventilator-free days until day 9 (days), median [IQR]	29 [29-29]	11 [0-20]	29 [29-29]	14 [0-22]	29 [29-29]	3 [0-19]	29 [29-29]	4 [0-16]	29 [29-29]	14 [1-22]	LSMD=-0.98 (-2.96 to 1.00) [P=0.33]	LSMD=-2.01 (-4.03 to 0.00) [P=0.05]	LSMD=0 (-1.93 to 2 [P=0.93
eath within 28 days, no. (%)	19 (5.1%)	35 (16.6%)	5 (5.3%)	7 (13.0%)	4 (4.3%)	10 (19.6%)	4 (4.4%)	13 (24.1%)	6 (6.5%)	5 (9.6%)	OR=1.24 (0.55 to 2.82) [P=0.60]	OR=1.51 (0.69 to 3.34) [P=0.30]	OR=0.9 (0.40 to 2. [P=0.88

medRxiv preprint doi: https://doi.org/10.1101/2021.01.08.20248149; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Table 3. Summary of adverse events according treatment group in the modified intention to treat population.

In the "Overall" column, numbers refer to number of events and number of patients. In other columns, number refer to number of patients (%). Some patients had more than a single SAE. Analyses were performed on the modified Intention-to-treat population. SAE, Serious Adverse Event. P-value refer to Fisher exact test.

- * Including renal failure in 30 patients, hepatic disorders in 18 patients and electrocardiogram abnormalities in 8 patients
- ** Excluding acute renal failures defined based on the RIFLE classification.

	Overall (N=579)	Control (N=148)	Lopinavir/ritonavir (L/r) (N=144)	Lopinavir/ritonavir + Interferon ß-1a (L/r + IFN) (N=144)	Hydroxychloroquine (HCQ) (N=143)	L/r vs. control	L/r + IFN vs. control	HCQ vs. control
	no. events / no. patients	no. patients (%)	no. patients (%)	no. patients (%)	no. patients(%)	P-value	P-value	P-value
Any adverse events	2399 / 450	105 (70.9%)	119 (82.6%)	117 (81.3%)	109 (76.2%)	0.02	0.04	0.35
Any grade 3 or 4 adverse events	477 / 205	48 (32.4%)	56 (38.9%)	58 (40.3%)	43 (30.1%)	0.27	0.18	0.71
Any serious adverse events	608 / 274	57 (38.5%)	76 (52.8%)	78 (54.2%)	63 (44.1%)	0.02	0.01	0.34
Premature suspension or discontinuation of the experimental treatment*	77 (13.3%)	-	17 (11.8%)	43 (29.9%)	17 (11.9%)	-	-	-
Most relevant SAEs								
- Acute respiratory failure	65 / 65	18 (12%)	19 (13%)	17 (12%)	11 (8%)			
- Acute Respiratory Distress syndrome	47 / 46	16 (11%)	7 (5%)	10 (7%)	13 (9%)			
- Acute kidney injury**	50 / 50	9 (6%)	16 (11%)	11 (8%)	14 (10%)			
- Acute renal failure based on the RIFLE classification	17 / 17	3 (2%)	3 (2%)	8 (6%)	3 (2%)			
- Arrhythmia	41 / 35	3 (2%)	8 (6%)	12 (8%)	12 (8%)			
- Pulmonary embolism	27 / 27	6 (4%)	10 (7%)	5 (3%)	6 (4%)			
- Transaminases increased	25 / 25	2 (1%)	5 (3%)	12 (8%)	6 (4%)			
- Sepsis	21 / 21	2 (1%)	6 (4%)	7 (5%)	6 (4%)			
- Cholestasis	6/6	0 (0%)	2 (1%)	3 (2%)	1 (1%)			